- Adial Pharmaceuticals, Inc. (ADIL) has been granted a **180-calendar day extension** by Nasdaq to regain compliance with the minimum $1.00 bid price requirement.  **[1513525_0001213900-25-083719_ea025574101ex99-1_adial.htm:0]** **[1513525_0001213900-25-083719_ea0255741-8k_adial.htm:1]** 
- The new deadline for the company to meet the Nasdaq Listing Rule 5550(a)(2) is **March 2, 2026**.  **[1513525_0001213900-25-083719_ea025574101ex99-1_adial.htm:0]** **[1513525_0001213900-25-083719_ea0255741-8k_adial.htm:1]** 
- To regain compliance, the company's common stock must maintain a closing bid price of at least **$1.00 per share for a minimum of ten (10) consecutive business days**.  **[1513525_0001213900-25-083719_ea025574101ex99-1_adial.htm:0]** 
- This extension has **no immediate effect** on the listing or trading of the company's shares on the Nasdaq Capital Market.  **[1513525_0001213900-25-083719_ea025574101ex99-1_adial.htm:0]** **[1513525_0001213900-25-083719_ea0255741-8k_adial.htm:1]** 
- The company intends to monitor its stock price and may consider a **reverse stock split** to cure the deficiency.  **[1513525_0001213900-25-083719_ea025574101ex99-1_adial.htm:0]** **[1513525_0001213900-25-083719_ea0255741-8k_adial.htm:1]**

ADIAL PHARMACEUTICALS (ADIL)